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Dear editor,
We would like to thank Osamu Imataki and his colleagues
[1] for their comments on our recent original article about a
real-life experience on the use of pegfilgrastim in primary
prophylaxis of febrile neutropenia (FN) for patients with
non-Hodgkin lymphoma (NHL) undergoing bendamustine
plus rituximab (BR) treatment [2]. Their case report is an
example of effectiveness of secondary prophylaxis with G-
CSF in a setting of advanced mantle cell lymphoma of an
elderly patient (82-year-old) who underwent BR [1]. The au-
thors want to highlight how BR could cause prolonged neu-
tropenia, especially during the following courses of therapy,
rather than the initial; therefore, a secondary G-CSF prophy-
laxis is probably advocated as more properly indicated. There
is still lack of data regarding the efficacy of a primary or
secondary prophylaxis with G-CSF in BR for patients with
NHL. However, our real-life experience suggests that, in a
primary prophylactic setting, pegfilgrastim seems to give sig-
nificant advantages in terms of reduction of FN-related che-
motherapy disruption incidence, with subsequent overall im-
provement of treatment effectiveness. Moreover, it was ob-
served that there is no significant G-CSF-related side effect
with pegfilgrastim primary prophylaxis, compared with Bon
demand^ secondary prophylaxis with filgrastim [2].
Considering the age of patients enrolled in our study, in the
pegfilgrastim group, the median was 45.4 years (range, 33–
77), with no patients > 80 years old.
Focusing on the aforementioned case report, the patient is
an 82-year-old frail patient, with many comorbidities and di-
agnosis of mantle cell lymphoma, so, who does not fully
match the overall elderly population risk, clinical course,
and outcome inmyelosuppressive therapy for an NHL. In fact,
elderly patients could gain the same benefits from chemother-
apy as young population, but, in most cases, the outcome is
poorer due the higher susceptibility on myelosuppression,
with the consequential use of reduced dose intensity regimen
that leads to reduction of effectiveness of treatment [3]. Then,
regardless of the treatment strategy, elderly patients are at high
risk of severe infections during FN, since first cycle of che-
motherapy potentially causes hospitalization, death, or sudden
and prolonged delay of treatment administration [3]. Despite
no specific data available on bendamustine-containing regi-
mens, and no specific indication on preferred primary prophy-
laxis, recent retrospective evaluation of G-CSF support in el-
derly patients with cancer revealed that up to 61.5% of pa-
tients with NHL and high risk of FN receive growth factor
support starting from the first cycle of chemotherapy [4].
Interestingly, our previous experience on primary prophy-
laxis with pegfilgrastim during bendamustine-based treat-
ment, not only in follicular lymphomas [5] but particularly
for another hematological malignancy, multiple myeloma,
typical to elderly age, had also been given interests for this
category of patients [6, 7]. In particular, patients treated with
bendamustine and receiving primary prophylaxis had a medi-
an age of 62.1 years (range, 43–83) and showed a significant
reduction in neutropenia-related infections and chemotherapy
disruption due to FN compared to those who received second-
ary prophylaxis [7]. This evidence shows that effectiveness of
pr imary prophylaxis wi th pegf i lgras t im, dur ing
bendamustine-containing therapy, is probably more effective
than secondary prophylaxis with non-pegylated G-CSF in
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elderly patients, regardless the type of lymphoproliferative
disease, also when totally different in terms of biology and
clinical behavior (lymphoma vs multiple myeloma). Other
interesting data could be extracted from other two case reports
by our Hematology Unit, where evaluation of supportive care
with G-CSF was not the first objective of the study, but its
effectiveness can be considered as part of the effectiveness of
multiple salvage lines of therapy, in patients with relapsed/
refractory multiple myeloma, including bendamustine-
containing regimens [8, 9]. Seven and 11 lines of therapy were
administered, respectively, to two old, frail, and heavily
pretreated patients with a long clinical history of relapsed
and refractory multiple myeloma: the support with pegylated
G-CSF was the backbone for the pursuance of each subse-
quent line of potentially myelotoxic therapy.
The evaluations of specific comorbidities and individual
risk factors for FN play also a key role on the decision of
whether adopting a primary or secondary prophylaxis with
G-CSF, but, in clinical practice, elderly age should be consid-
ered a strong parameter that drives to the choice of a primary
prophylaxis. Our aim is also to highlight that, in an outpatient
setting, using pegfilgrastim is very feasible and manageable,
thanks also to its modality of administration that can reduce
the necessity of caregivers’ work.
In conclusion, we want to support the idea that a great
advantage in terms of quality of life, effectiveness of ther-
apy, and outcome could derive from a primary prophylax-
is with easily manageable administration of pegfilgrastim,
especially in advanced-age patients, such as the one de-
scribed in the case report by Imataki et al., in which min-
imizing the risk of a FN since the first course can be the
key for the best outcome.
Publisher’s note Springer Nature remains neutral with regard to jurisdic-
tional claims in published maps and institutional affiliations.
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